Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegnivacogin
- Development stage
- Phase 2
- Lead developer
- Allergan
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Pegnivacogin is a 2′-fluoropyrimidine–modified RNA aptamer that directly and selectively inhibits coagulation factor IXa. It is conjugated to a branched methoxypolyethylene glycol (mPEG) molecule to increase its plasma half-life and concentration. Pegnivacogin was developed as part of the REG1 anticoagulation system, which also includes anivamersen, a complementary oligonucleotide reversal agent. The drug was investigated for use in acute coronary syndrome, thrombosis, coronary artery disease, and vascular diseases. Clinical trials showed that pegnivacogin achieves rapid and near-complete inhibition of factor IXa activity in patients with acute coronary syndrome undergoing cardiac catheterization. However, development was discontinued after reports of severe allergic reactions during clinical studies[4][6][8].
- Other names
- pegnivacogin sodium959716-28-0AYC3D1NPYBAYC-3D1NPYBAYC 3D1NPYB
02
Targets
Coagulation Factor IXa
Beyond the preview
Go deeper on pegnivacogin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegnivacogin.